Diclofenac EP Impurity D, chemically identified as 2-[2-[(2-Bromo-6-chlorophenyl)amino]phenyl]acetic acid and also recognized as the Diclofenac Bromo Analog, is a halogen-substituted diarylamine impurity of Diclofenac, with molecular formula C₁₄H₁₁BrClNO₂ and molecular weight 340.60 g/mol. Structurally, it differs from the parent NSAID by a bromine atom in place of one of the two ortho-chlorine atoms on the anilino ring. This impurity is typically traced to 2-bromo-6-chloroaniline present as a contaminant in the 2,6-dichloroaniline starting material, which is then carried through the diarylamine-forming and subsequent synthetic steps. Owing to this origin, the compound serves as an important process-related impurity marker for evaluating starting-material quality and synthetic-route control across Diclofenac Sodium and Diclofenac Potassium production. Manufactured at Chemicea under precisely controlled synthetic and analytical protocols, this reference standard supports impurity identification, method validation (AMV), and quality-control testing in accordance with EP and BP monograph requirements, and is routinely applied in ANDA and DMF regulatory submissions. Each batch is supplied with a comprehensive Certificate of Analysis supported by HPLC, ¹H-NMR, and Mass Spectrometry characterization data, ensuring dependable analytical traceability for pharmaceutical R&D and QC laboratories. CAS No. 127792-23-8 (sodium salt CAS No. 127792-45-4) | Explore complete technical documentation, Safety Data Sheet (SDS), and pricing.